Meta-analysis finds germline LTS and somatic TERT variants are mutually exclusive in thyroid cancer and melanoma
This is a meta-analysis of retrospective observational cohort data from 18 cancer centers. It examined germline long-telomere syndrome (LTS) variants (POT1, TINF2, ACD) and somatic TERT promoter variants or fusions in adults with non-medullary thyroid cancer (NMTC) and melanoma. The sample included 995 adults with NMTC and 993 with melanoma. The primary synthesis found that germline LTS-associated pathogenic or likely pathogenic variants and somatic TERT alterations were mutually exclusive (p=0.036).
In NMTC, 13 of 995 patients (1.5%) had a germline LTS variant, while 0 of 12 patients with available data had somatic TERT promoter variants or fusions. In melanoma, 7 of 993 patients (0.7%) had a germline LTS variant, and 0 of 2 patients had somatic TERT alterations. High telomerase mRNA levels were associated with TERT promoter variants or fusions (p<4e-11) and with larger NMTC or distant metastases (p=0.016), but not with germline LTS variants.
The authors noted that NMTCs with somatic TERT promoter variants or fusions had higher tumor mutation burden than those with germline LTS variants (p<0.02). TERT promoter mutant variant allele frequency was lower in smaller and non-metastatic NMTC compared to larger or metastatic disease. A key limitation is that the genetic relationship between these variants and their clinical associations is defined incompletely.
Practice relevance is restrained: germline LTS-associated variants appear exclusive from somatic TERT alterations but are not associated with aggressive NMTC, suggesting common roles in tumorigenesis with different biological impacts. The study assesses associations; causality is not explicitly claimed beyond the exclusivity finding.